Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRAS^G12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).

Authors

Marwan Fakih

City of Hope National Medical Center, Duarte, CA

Marwan Fakih , Greg Andrew Durm , Ramaswamy Govindan , Gerald Steven Falchook , Neelesh Soman , Haby Adel Henary , David S. Hong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRAS^G12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).

First Author: David S. Hong

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours.

First Author: Samuel John Harris

insert_chart_outlined

Poster

2021 Gastrointestinal Cancers Symposium

bookmark_border

MEKiAUTO: A phase I/II open-label study of combination therapy with the MEK inhibitor cobimetinib, Immune-checkpoint blockade with atezolizumab, and the AUTOphagy inhibitor hydroxychloroquine in KRAS-mutated advanced malignancies.

First Author: Alexander Raufi

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

CodeBreak 100: Phase I study of AMG 510, a novel KRAS^G12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

First Author: David S. Hong